Genomic analyses for the GO30140 phase Ib and IMbrave150 phase 3 trial of atezolizumab and bevacizumab in patients with HCC reported that high expression of PD-L1, as per RNA-seq, is related to better response and longer PFS [37]. This evidence concerns the gene CD274 and hepatocellular carcinoma.